Article
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Antiviral therapy - 1 Jan 2017
Rockstroh Jürgen K, Ingiliz Patrick, Petersen Jörg, Peck-Radosavljevic Markus, Welzel Tania M, Van der Valk Marc, Zhao Yue, Jimenez-Exposito Maria Jesus, Zeuzem Stefan
Abstract excerpt
BACKGROUND: HIV-HCV-coinfected patients respond just as well to modern direct-acting antiviral HCV therapy as HCV-monoinfected patients. However, clinical data for all-oral HCV treatments are sparse in HIV-HCV-coinfected patients with an advanced stage of liver cirrhosis. METHODS: A subanalysis of efficacy and safety for a daclatasvir (DCV) and sofosbuvir (SOF) regimen, with or without ribavirin (RBV), was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.